Dr. Habeebbullal Life Sciences Ltd (BSE: 539267) is a Hyderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹28 Cr, it ranks #4,328 by market cap among the 6,137 Indian listed companies on FinBizNet, and #9 of 10 in Life Sciences Tools and Services. At ₹13.42 (as of 25 Oct 2026), the share price is 46.9% below its 52-week high of ₹25.27 and 32.2% above its 52-week low of ₹10.15. The share price is down 32.7% over one year and up 8.7% over three months.
| Current Price | ₹13.42 |
|---|---|
| Market Cap | ₹28 Cr |
| BSE Code | 539267 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | -2.8 |
| Return on Equity | -68.79% |
| Return on Assets | -36.38% |
| 52-Week Range | ₹10.15 – ₹25.27 |
| 1-Year Price Change | -32.7% |
| 3-Month Price Change | +8.7% |
| Beta (1Y) | -0.44 |
| Headquarters | Hyderabad, Telangana |
| Website | drhlsl.com |
Samsrita Labs Limited operates as a biopharmaceutical company in India. The company offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. It is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, company engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiova
1. Healthcare Services-This segment engages in the bio-pharma business. It offers DNA and RNA based tests for infectious diseases, oncology, endocrinology, transplantation typing, haematology, pharmacogenetics, and pre-natal and pre-implantation genetic diagnostics; and karyotype fluorescence in-situ hybridization analysis to detect targeted chromosome abnormalities.
1. Healthcare Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,413 Cr | 35.2 | 13.94% | ₹1,063 Cr | +5.9% |
| Suven Life Sciences Ltd. | ₹8,583 Cr | -24 | -78.80% | ₹4 Cr | +30.6% |
| Vimta Labs Ltd | ₹2,338 Cr | 29.3 | 18.55% | ₹109 Cr | -32.5% |
| Tarsons Products Limited | ₹1,762 Cr | 117.2 | 2.26% | ₹110 Cr | +3.3% |
| Bilcare Ltd. | ₹224 Cr | 122.4 | -5.21% | — | — |
| Brooks Laboratories Ltd. | ₹199 Cr | 8.1 | 22.28% | ₹23 Cr | -53.0% |
| Jeevan Scientific Technology Ltd | ₹178 Cr | 130.4 | 1.68% | — | +34.0% |
| Vivo Bio Tech Ltd. | ₹31 Cr | -16.6 | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹28 Cr | -2.8 | -68.79% | — | -32.7% |
Listed by market capitalisation. Ratios are shown for context only.
Dr. Habeebbullal Life Sciences Ltd is trading at ₹13.42, with a market capitalisation of ₹28 Cr.
Dr. Habeebbullal Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Dr. Habeebbullal Life Sciences Ltd has a P/E of -2.8 and a return on equity of -68.79%.
Dr. Habeebbullal Life Sciences Ltd is listed on the BSE under the scrip code 539267.
Dr. Habeebbullal Life Sciences Ltd's share price is down 32.7% over one year and up 8.7% over three months. Its 52-week range is ₹10.15 to ₹25.27.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.